Literature DB >> 23450849

Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.

Shinji Matsumoto1, Kazuki Nabeshima, Toshiaki Kamei, Kenzo Hiroshima, Kunimitsu Kawahara, Sakae Hata, Katsuji Marukawa, Yoshihiro Matsuno, Kenichi Taguchi, Tohru Tsujimura.   

Abstract

BACKGROUND: In malignant pleural mesothelioma (MPM), most patients first present with pleural effusion; thus, cytologic analysis is the primary diagnostic approach. However, the cytologic distinction between MPM and reactive mesothelial cells (RMCs) in effusions can be extremely difficult due to the lack of both well-established immunocytochemical markers and definite cytological criteria for MPM. Moreover, the existence of both MPM cells and RMCs in effusions from the same patient makes the differentiation even more challenging. Homozygous deletion of the 9p21 locus, the site of the cyclin-dependent kinase inhibitor 2A/p16 (CDKN2A/p16) gene, frequently occurs in MPM but has never been reported in RMCs. The aim of this study was to define the cytomorphological characteristics of MPM cells, identified by the presence of 9p21 homozygous deletion by fluorescence in situ hybridization (FISH).
METHODS: For this purpose, cells on smear preparations were recorded using a virtual microscope system and were subjected to FISH analysis. Thereafter, 9p21 homozygous deletion-positive cells were identified in the recorded virtual slides, followed by analysis of their morphological characteristics.
RESULTS: Mesothelioma cells positive for the 9p21 homozygous deletion exhibited significantly more frequent cell-in-cell engulfment, multinucleation (more than 2 nuclei), and larger multicellular clusters composed of more than 10 cells than did 9p21 deletion-negative RMCs. Possible cutoff values are also proposed for these morphological markers to differentiate MPM cells from RMCs.
CONCLUSIONS: These morphological differences and cutoff values are useful for cytological differentiation of mesothelioma cells from RMCs. In addition, the novel technique of a combination of virtual microscopy and FISH is introduced for tumor morphological analysis.
Copyright © 2013 American Cancer Society.

Entities:  

Keywords:  9p21 homozygous deletion; cytology; fluorescence in situ hybridization; p16; pleural mesothelioma

Mesh:

Year:  2013        PMID: 23450849     DOI: 10.1002/cncy.21269

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  12 in total

1.  Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.

Authors:  Yoshiaki Kinoshita; Makoto Hamasaki; Masayo Yoshimura; Shinji Matsumoto; Akinori Iwasaki; Kazuki Nabeshima
Journal:  Mod Pathol       Date:  2019-06-23       Impact factor: 7.842

2.  Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.

Authors:  Shinji Matsumoto; Kazuki Nabeshima; Makoto Hamasaki; Tatsuki Shibuta; Tsukuru Umemura
Journal:  Med Oncol       Date:  2014-10-31       Impact factor: 3.064

Review 3.  Pleural mesothelioma classification update.

Authors:  Mary Beth Beasley; Francoise Galateau-Salle; Sanja Dacic
Journal:  Virchows Arch       Date:  2021-01-21       Impact factor: 4.064

4.  MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.

Authors:  R F H Walter; F D Mairinger; S Ting; C Vollbrecht; T Mairinger; D Theegarten; D C Christoph; K W Schmid; J Wohlschlaeger
Journal:  Br J Cancer       Date:  2015-02-10       Impact factor: 7.640

5.  Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.

Authors:  Tomoyuki Hida; Shinji Matsumoto; Makoto Hamasaki; Kunimitsu Kawahara; Tohru Tsujimura; Kenzo Hiroshima; Toshiaki Kamei; Kenichi Taguchi; Akinori Iwasaki; Yoshinao Oda; Hiroshi Honda; Kazuki Nabeshima
Journal:  Cancer Sci       Date:  2015-10-15       Impact factor: 6.716

Review 6.  Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology.

Authors:  Anders Hjerpe; Valeria Ascoli; Carlos Bedrossian; Mathilde Boon; Jenette Creaney; Ben Davidson; Annika Dejmek; Katalin Dobra; Ambrogio Fassina; Andrew Field; Pinar Firat; Toshiaki Kamei; Tadao Kobayashi; Claire W Michael; Sevgen Önder; Amanda Segal; Philippe Vielh
Journal:  Cytojournal       Date:  2015-11-30       Impact factor: 2.091

7.  PCDH7 Inhibits the Formation of Homotypic Cell-in-Cell Structure.

Authors:  Chenxi Wang; Ang Chen; Banzhan Ruan; Zubiao Niu; Yan Su; Hongquan Qin; You Zheng; Bo Zhang; Lihua Gao; Zhaolie Chen; Hongyan Huang; Xiaoning Wang; Qiang Sun
Journal:  Front Cell Dev Biol       Date:  2020-05-08

8.  Cytogenomic characterization of three murine malignant mesothelioma tumor cell lines.

Authors:  Eva Wahlbuhl; Thomas Liehr; Martina Rincic; Shaymaa Azawi
Journal:  Mol Cytogenet       Date:  2020-09-09       Impact factor: 2.009

9.  Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met.

Authors:  Keisuke Satoh; Satoshi Nimura; Mikiko Aoki; Makoto Hamasaki; Kaori Koga; Hiroshi Iwasaki; Yuichi Yamashita; Hiroaki Kataoka; Kazuki Nabeshima
Journal:  Cancer Sci       Date:  2014-10-09       Impact factor: 6.716

10.  Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma.

Authors:  Clément Meiller; François Montagne; Theo Z Hirsch; Stefano Caruso; Julien de Wolf; Quentin Bayard; Jean-Baptiste Assié; Léa Meunier; Yuna Blum; Lisa Quetel; Laure Gibault; Ecaterina Pintilie; Cécile Badoual; Sarah Humez; Françoise Galateau-Sallé; Marie-Christine Copin; Eric Letouzé; Arnaud Scherpereel; Jessica Zucman-Rossi; Françoise Le Pimpec-Barthes; Marie-Claude Jaurand; Didier Jean
Journal:  Genome Med       Date:  2021-07-14       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.